This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Jim Cramer: The Only Data Point That Matters

NEW YORK (Real Money) -- Take a look at what worked in the fourth quarter. If you do, you can see why I write -- right up top in Get Rich Carefully -- that the only economic metric worth following is the payroll employment number that comes out on the first Friday of every month.

First, let me say: We are bombarded with numbers. We have all sorts of them -- purchasing managers reports; retail sales; new and used home sales; durable goods; consumer confidence; inflation, both producer and consumer; Federal Reserve minutes; and the index of home pricing.

I don't want to say, "Throw these away, they mean nothing." They can impact the pricing in U.S. Treasury bonds, at least ephemerally. They must be reported because they are, indeed, news. But for the most part they have no lasting impact, almost none whatsoever, at least when compared with that payroll report. This was the number that predicted the downturn, and it was the number that led to a wholesale shift in stock focus -- the big rotation -- in the fourth quarter. This was vital when it came to picking the right stocks that outperformed, and outperformed substantially, in the latter half of the year.

I know that might seem unfair to those who make a big deal of every number, but let's look at what happened in the fourth quarter.

First, as soon as the first good number showed up, investors started dumping everything that was soft goods or recession-related, including General Mills (GIS), Kellogg (K), Eli Lilly (LLY), Pfizer (PFE) and Johnson & Johnson (JNJ). It was almost as if these stocks caught the plague. If you had stayed with them or hadn't cut them back because you had wanted to be diversified -- something I wouldn't have blamed you one bit for -- your portfolio would have stopped increasing in value. It would have just hit a wall.

It is important to recognize that the same idea generally applied to the drugmakers. Unless there was a new breakthrough drug or approval -- as was the case with Gilead (GILD) and its hepatitis C drug, newly sanctioned by the Food and Drug Administration -- the same underperformance struck hard there, too after the big employment number. It just stopped this once-red-hot group in its tracks.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,695.48 -80.64 -0.45%
S&P 500 2,054.32 -13.57 -0.66%
NASDAQ 4,857.2220 -43.6630 -0.89%

Our Tweets

Partners Compare Online Brokers

Top Rated Stocks Top Rated Funds Top Rated ETFs